May 3, 2021 11:04 AM EDT

News briefing: Gyroscope and Talaris set IPO terms; FDA grants expanded nod to Chiesi's sickle cell drug

Max Gelman

Senior Editor

Josh Sullivan

In a week where two biotech IPOs were already expected, another two prospective entrants have set their debut terms ahead of their launch later this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News briefing: Gyroscope and Talaris set IPO terms; FDA grants expanded nod to Chiesi's sickle cell drug

Max Gelman

Senior Editor

Josh Sullivan

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

News brief­ing: Gy­ro­scope and Ta­laris set IPO terms; FDA grants ex­pand­ed nod to Chiesi's sick­le cell drug

Senior Editor

Sign up to read this article for free.

News briefing: Gyroscope and Talaris set IPO terms; FDA grants expanded nod to Chiesi's sickle cell drug